Holen Sie sich die Stockscreener-App
2.12
0.95%
0.02
Handel nachbörslich:
2.10
-0.02
-0.94%
Schlusskurs vom Vortag:
$2.10
Offen:
$2.2
24-Stunden-Volumen:
22,344
Relative Volume:
0.37
Marktkapitalisierung:
$6.63M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-17.85M
KGV:
-0.0572
EPS:
-37.0644
Netto-Cashflow:
$-13.02M
1W Leistung:
+12.77%
1M Leistung:
-30.72%
6M Leistung:
-84.47%
1J Leistung:
-92.71%
1-Tages-Spanne:
$2.09
$2.20
1-Wochen-Bereich:
$1.93
$2.40
52-Wochen-Spanne:
$1.6495
$51.75
Silexion Therapeutics Corp Stock (SLXN) Company Profile
Firmenname
Silexion Therapeutics Corp
Sektor
Branche
Telefon
972-8-6286005
Adresse
12 ABBA HILLEL ROAD, RAMAT GAN
Vergleichen Sie SLXN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SLXN
Silexion Therapeutics Corp
|
2.12 | 6.57M | 0 | -17.85M | -13.02M | -37.06 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Silexion Therapeutics Corp Aktie (SLXN) Neueste Nachrichten
Can Silexion Therapeutics Corp Equity Warrant stock sustain free cash flow growthJuly 2025 Opening Moves & Fast Gain Swing Alerts - ulpravda.ru
Can Silexion Therapeutics Corp Equity Warrant stock beat market expectations this quarterRecession Risk & Fast Exit Strategy with Risk Control - ulpravda.ru
Dividend Watch: Will Silexion Therapeutics Corp stock deliver strong dividend growthPortfolio Risk Summary & Fast Moving Market Watchlists - ulpravda.ru
Why Silexion Therapeutics Corp Equity Warrant stock attracts high net worth investorsFit and Size Notes & quick comparison of popular models - ulpravda.ru
Is Silexion Therapeutics Corp stock a buy for dividend growthJuly 2025 Final Week & Short-Term Trading Opportunity Alerts - ulpravda.ru
Why retail investors favor Silexion Therapeutics Corp stockQuarterly Market Review & Free High Accuracy Swing Entry Alerts - ulpravda.ru
How strong is Silexion Therapeutics Corp stock revenue growthProduct Launch & Entry Point Confirmation Signals - ulpravda.ru
Will Silexion Therapeutics Corp stock deliver strong dividend growthPortfolio Risk Summary & Fast Moving Market Watchlists - ulpravda.ru
What momentum indicators show for Silexion Therapeutics Corp Equity Warrant stockMarket Performance Recap & Free Long-Term Investment Growth Plans - ulpravda.ru
Will Silexion Therapeutics Corp Equity Warrant stock reach Wall Street targetsJuly 2025 Spike Watch & Daily Entry Point Trade Alerts - ulpravda.ru
Can Silexion Therapeutics Corp stock weather global recession2025 Price Action Summary & Short-Term High Return Strategies - ulpravda.ru
Signal Recap: What technical signals suggest for Silexion Therapeutics Corp stockWeekly Market Report & Consistent Growth Equity Picks - ulpravda.ru
Will Silexion Therapeutics Corp stock outperform Dow Jones indexTrade Entry Summary & Community Driven Trade Alerts - ulpravda.ru
Silexion Therapeutics CorpOrdinary Shares (NQ: SLXN - FinancialContent
Silexion outlines 2026 plans after transformational 2025 progress - TipRanks
Silexion Therapeutics Corp Highlights 2025 Achievements and 2026 Milestones - TradingView — Track All Markets
Silexion Therapeutics' Cancer Drug to Enter Human Trials in Early 2026 - MarketScreener
Silexion Therapeutics Reports Promising Preclinical Results for SIL204 in KRAS-Driven Cancers and Plans Phase 2/3 Trial Initiation for 2026 - Quiver Quantitative
Silexion Therapeutics Releases CEO Letter to Shareholders - GlobeNewswire
Cash per share of Silexion Therapeutics Corp Warrant – NASDAQ:SLXNW - TradingView — Track All Markets
Merger Talk: Is Silexion Therapeutics Corp Equity Warrant stock trading at a premium valuation2025 Top Decliners & Daily Volume Surge Signals - moha.gov.vn
Risk Hedge: Will Silexion Therapeutics Corp stock deliver strong dividend growth2025 Market Overview & Safe Capital Growth Stock Tips - moha.gov.vn
Can Silexion Therapeutics Corp Equity Warrant stock hit analyst price targetsJuly 2025 Retail & Free Technical Pattern Based Buy Signals - Улправда
Can Silexion Therapeutics Corp Equity Warrant stock hit record highs againJuly 2025 Weekly Recap & Daily Chart Pattern Signal Reports - Улправда
Will Silexion Therapeutics Corp Equity Warrant stock pay special dividendsTrade Exit Report & Weekly Top Performers Watchlists - DonanımHaber
How Silexion Therapeutics Corp stock compares to growth peersQuarterly Performance Summary & Free Real-Time Market Sentiment Alerts - DonanımHaber
Risk Analysis: Can Silexion Therapeutics Corp Equity Warrant stock hit analyst price targetsPortfolio Risk Report & High Conviction Trade Alerts - Улправда
Treasury Yields: How strong is Silexion Therapeutics Corp stock revenue growthWeekly Trade Report & AI Based Buy and Sell Signals - DonanımHaber
Silexion Therapeutics (NASDAQ:SLXN) Upgraded at Zacks Research - Defense World
Can Silexion Therapeutics Corp stock sustain free cash flow growth2025 Year in Review & Fast Exit/Entry Strategy Plans - Улправда
Gains Report: Will Silexion Therapeutics Corp Equity Warrant stock reach Wall Street targetsJuly 2025 Recap & AI Driven Stock Price Forecasts - Улправда
Stop Loss: Can Silexion Therapeutics Corp Equity Warrant stock hit record highs again - Улправда
Silexion Therapeutics submits Phase 2/3 trial application - MSN
Silexion Therapeutics Submits Phase 2/3 Trial Application - TipRanks
Silexion submits Phase 2/3 trial application to Israel for SIL204 - TipRanks
Silexion Therapeutics Submits Phase 2/3 Trial Application for SIL204 - TradingView — Track All Markets
Silexion Therapeutics Advances Regulatory Submission for Phase 2/3 Trial of SIL204 in Pancreatic Cancer - Quiver Quantitative
Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for Sil204 in Locally Advanced Pancreatic Cancer - marketscreener.com
Silexion Therapeutics (NASDAQ:SLXN) Now Covered by Litchfield Hills Research - Defense World
Silexion Therapeutics Announces Submission of Phase 2/3 - GlobeNewswire
Silexion Therapeutics initiated with a buy at Litchfield Hills - MSN
Silexion Therapeutics initiated with a Buy at Litchfield Hills - TipRanks
Bearish Setup: Is Silexion Therapeutics Corp Equity Warrant stock recession proof2025 Momentum Check & AI Forecasted Entry/Exit Points - moha.gov.vn
Silexion Shares Decline After Update on German Regulatory Review - MSN
Silexion Therapeutics (SLXNW) Stock Analysis Report | Financials & Insights - Benzinga
How buybacks impact Silexion Therapeutics Corp stock valueProfit Target & Intraday High Probability Setup Alerts - Newser
Buy Recommendation for Silexion Therapeutics: Promising Developments and Market Potential in Pancreatic Cancer Treatment - TipRanks
Silexion Therapeutics drops 18%, prices $5M share offering - MSN
Silexion receives positive feedback from German Health Authority for SIL204 - TipRanks
Silexion Therapeutics (SLXN) Stock Analysis Report | Financials & Insights - Benzinga
Silexion stock falls after receiving German regulatory feedback By Investing.com - Investing.com Canada
Finanzdaten der Silexion Therapeutics Corp-Aktie (SLXN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):